Search results for "L. Bueno. Mechanisms involved in bacterial pathogen-induced intestinal mucosal barrier disruption: Therapeutic interest of mecha"

The first clinical evidence related to an hydrogel based on Olea europaea leaf extract (EHO‐85) indicated for the healing of wounds of full and partial thickness has been published in the Journal of Clinical Medicine.
TASECTAN® launched in Croatia by JGL. Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop. TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and infants.
News on NOVENTURE participation at EAU 2019 in BARCELONA For the fourth consecutive year, Noventure was present at the annual congress of the EAU - European Association of Urology- that took place in Barcelona 15th – 19th March 2019.
New publication for Utipro® Plus
Current Medical Research and Opinion 2017.  June 10: 1-17 Background: This study assessed the efficacy, safety and tolerability of a xyloglucan-based nasal spray in the treatment of symptoms of rhinosinusitis.
Curr Med Res Opin. 2014 Jun;30(6):1131-7. doi: 10.1185/03007995.2014.882299. Epub 2014 Jan 30.2:3. Background and objectives: Barrier-enforcing measures have been suggested as treatment options for allergic rhinitis. This review identifies and describes the literature on the subject.
Paediatr Drugs. 2016 Dec 20. doi: 10.1007/s40272-016-0207-z Background:
Adiarin®  is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia.
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants.
UTIPRO® PLUS AF Utipro® Plus AF is intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.